Sight Sciences Reports New Agreements, Debt, and Equity Sales

TL;DR

**Sight Sciences just made big moves with new debt and equity sales, signaling potential strategic shifts.**

AI Summary

Sight Sciences, Inc. filed an 8-K on January 23, 2024, reporting several significant events that occurred on January 22, 2024. These include entering into and terminating material definitive agreements, creating a direct financial obligation, and engaging in unregistered sales of equity securities. This matters to investors because these actions could signal a strategic shift, new financing, or changes in the company's operational structure, potentially impacting future growth and profitability.

Why It Matters

This filing indicates significant corporate actions, including new financial obligations and equity sales, which could affect the company's capital structure and future financial performance.

Risk Assessment

Risk Level: medium — The combination of new financial obligations and unregistered equity sales introduces complexity and potential dilution, warranting a medium risk assessment.

Analyst Insight

A smart investor would investigate the details of the new agreements, financial obligations, and equity sales once they become public to assess their impact on the company's valuation and future prospects.

Key Players & Entities

• Sight Sciences, Inc. (company) — the registrant filing the 8-K
• January 22, 2024 (date) — date of the earliest event reported
• January 23, 2024 (date) — date the 8-K was filed

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share SGHT The Nasdaq
• $65.0 million — the aggregate principal amount of up to $65.0 million (the "Term Loan Facility"). An initial
• $35.0 million — Loan Facility"). An initial tranche of $35.0 million (the "Initial Loan") was funded under t
• $5.0 million — ditional tranches available as follows: $5.0 million available in a single draw through Dece
• $10.0 million — tial Loan, the "Tranche I Commitment"), $10.0 million available to draw between the period co
• $15.0 million — , and ending on September 15, 2025, and $15.0 million available for Borrower to draw through
• $5.0 m — erformance milestones) in increments of $5.0 million, subject to the sole approval of
• $34.6 m — net proceeds from the Initial Loan were $34.6 million, after deducting estimated debt i
• $37.7 million — 1.02 below) in the aggregate amount of $37.7 million. Interest Rate, Facility Charge, Warr
• $700,000 — qual to two percent of Initial Loan, or $700,000, divided by the volume-weighted average
• $3 million — s the option to invest up to a total of $3 million in Borrower's next round of equity offe
• $400,000,000 — ins a market capitalization of at least $400,000,000. The foregoing summary of the Term Lo

Filing Documents

• d715146d8k.htm (8-K) — 41KB
• d715146dex41.htm (EX-4.1) — 80KB
• d715146dex101.htm (EX-10.1) — 897KB
• d715146dex991.htm (EX-99.1) — 11KB
• g715146dsp118.jpg (GRAPHIC) — 2KB
• g715146g0123144526750.jpg (GRAPHIC) — 4KB
• g715146g0123151836895.jpg (GRAPHIC) — 2KB
• g715146g0123151837239.jpg (GRAPHIC) — 1KB
• g715146g0123151837570.jpg (GRAPHIC) — 2KB
• g715146g0123151838258.jpg (GRAPHIC) — 2KB
• g715146g0123151838615.jpg (GRAPHIC) — 2KB
• g715146g0123151838966.jpg (GRAPHIC) — 2KB
• g715146g0123151839367.jpg (GRAPHIC) — 2KB
• g715146g715146c.jpg (GRAPHIC) — 2KB
• g715146g715146part2b.jpg (GRAPHIC) — 6KB
• 0001193125-24-012979.txt ( ) — 1362KB
• sght-20240122.xsd (EX-101.SCH) — 3KB
• sght-20240122_lab.xml (EX-101.LAB) — 18KB
• sght-20240122_pre.xml (EX-101.PRE) — 11KB
• d715146d8k_htm.xml (XML) — 3KB

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 4.1 Form of Warrant 10.1 Loan and Security Agreement, dated January 22, 2024, by and among Sight Sciences, Inc., certain affiliates of Hercules Capital, Inc., and Hercules Capital., Inc.+ 99.1 Press Release, dated January 23, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) + Portions of this exhibit are redacted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The Company agrees to furnish an unredacted copy of such exhibit, or a copy of any omitted schedule or exhibit, to the Securities and Exchange Commission upon request.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sight Sciences, Inc. Date: January 23, 2024 By: /s/ Alison Bauerlein Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR